Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. director Shalini Sharp filed an amended Form 3 to correct her initial insider holdings. The amendment now reflects ownership of 9 American Depositary Shares, held directly. A footnote explains that each ADS represents 13 Ordinary Shares. This update does not report any new buy or sell transactions; it simply adds ADS that were omitted from the original Form 3 and subsequent Forms 4, leaving all other previously reported information unchanged.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised employee share options covering 4,316 Ordinary Shares at exercise prices of $12.23, $16.41, and $14.96 per share. The options were represented as Share Options (Right to Buy) and convert into Ordinary Shares.
On the same date, he sold 332 American Depositary Shares at an average price of $310.72 per ADS in an open-market transaction made under a Rule 10b5-1 trading plan. Following these transactions, he directly owns 318,370 Ordinary Shares and no American Depositary Shares.
BeOne Medicines Ltd. reports that the U.S. FDA has granted accelerated approval for BEQALZI (sonrotoclax), a next-generation BCL2 inhibitor, to treat adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies, including a BTK inhibitor.
The decision is based on a Phase 1/2 study showing a 52% overall response rate, a 16% complete response rate, and a median duration of response of 15.8 months. Approval is conditional on confirmatory trial results, and the label carries important safety warnings, including tumor lysis syndrome and serious infections.
BeOne Medicines Ltd. ownership update: Capital International Investors filed an amendment to report beneficial ownership of 65,211,266 shares, representing 4.2% of the class based on 1,540,975,898 shares outstanding. The filing states CII has sole voting power over 64,349,154 shares and sole dispositive power over 65,211,266 shares. The report also notes 4,638,440 Depository Receipts that the filer says represent 60,299,720 Common Stock.
ONC submitted a Form 144 reporting the proposed sale of 1,328 ADS on 05/13/2026 following an exercise of stock options. The filing also discloses prior Rule 10b5-1 sales of 332 ADS on 04/08/2026 for $103,447.88 and 341 ADS on 03/11/2026 for $102,300.00.
BeOne Medicines Ltd. filed a post-effective Form S-3 shelf registration to replace an expiring registration, registering up to 398,880,905 Ordinary Shares, including 374,373,961 Ordinary Shares represented by 28,797,997 ADSs (each ADS = 13 Ordinary Shares). The prospectus states BeOne is not selling any shares here and will not receive proceeds; proceeds, if any, will go to the listed selling shareholders. The registration covers resale by Amgen, entities affiliated with Baker Bros. Advisors and HHLR Advisors under existing registration rights. The filing notes cross‑listings on HKEx, Nasdaq and the STAR Market and highlights business, liquidity and China‑related operational risk disclosures incorporated by reference.
BeOne Medicines Ltd. files a new shelf registration on Form S-3 to replace an expiring registration and permit, from time to time, primary offerings and resales of ordinary shares, ADSs, preferred shares, debt securities, warrants and units.
The shelf contemplates offerings by the company and selling shareholders, with proceeds to the company disclosed only in future prospectus supplements; the company discloses key context figures including $731 million in cash and cash equivalents as of March 31, 2026, approximately 1,540,975,898 Registered Shares issued, and recent product and pipeline highlights (BRUKINSA sales of $3.9 billion in 2025). The registration replaces an earlier S-3 that would expire on May 9, 2026.